New Speciality Pharma Customer for New Indication

RNS Number : 8058J

Physiomics PLC

22 December 2015

 

Physiomics plc

("Physiomics") or ("the Company")

New Speciality Pharma Customer for new Indication

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a new contract with another new speciality pharma customer, to perform PK/PD modelling analysis for a novel combination and translate the results into the clinic. This will be the Company's first project related to drugs treating pain.

The project will be performed on a fee-for-service basis.

Dr Mark Chadwick, CEO of Physiomics, commented:

"We are extremely pleased to have added another new customer for a fee-paying commercial project. We are also happy to have expanded our services beyond oncology into treating pain.  We hope to gain further business with this customer and similar clients in the future."

Enquiries:

Physiomics plc                                                  

Dr Mark Chadwick, CEO

[phone]

WH Ireland Limited (broker/nomad)

Katy Mitchell

[phone]

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million¹.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

¹Tufts Centre Impact Report 2002

 

END

 

 

CNTFEIFUFFISESE